Strategic acquisition LimFlow has been acquired by Inari Medical, signaling a potential channel shift and larger sales umbrella. This suggests opportunities to align with Inari's distributor and customer base, leverage broader sales resources, and pursue cross-sell of LimFlow’s deep vein arterialization system to existing Inari customers.

High‑value addressable market The target patients are those with Chronic Limb-Threatening Ischemia who are facing amputation. This creates a compelling value proposition for hospitals and payers seeking limb-salvage outcomes, enabling premium pricing discussions around amputation avoidance and wound healing improvements.

Clinical impact credibility PROMISE I study results and ongoing clinical data underpin adoption in centers treating end-stage CLTI. Use these outcomes in sales collateral to accelerate clinical buy-in, shorten procurement cycles, and justify reimbursement strategies with health economics teams.

Rising partnerships Historically strategic collaborations with MD Start and NAMSA highlight a proven path for clinical validation and study support. Leverage these partnerships to propose joint studies, registries, or expanded real-world evidence programs to potential hospital customers.

Funding and growth trajectory With Series D funding and a recent multi‑million valuation touchpoint prior to acquisition, there is investor confidence in LimFlow’s technology. Use this momentum in conversations with procurement and finance teams to justify scalable deployment, training programs, and long-term service agreements.